|
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We investigated linkage between schizophrenia and the loci DXYS14, DXYS17, and MIC2 within the pseudoautosomal region in 85 families with two or more siblings suffering from schizophrenia or schizoaffective disorder.
|
7818635 |
1994 |
|
Mesenchymal Chondrosarcoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
The results showed that malignant mesenchymal chondroblasts exhibit stronger expressions of CD99, IL-1alpha, cPKC-alpha, p-PKC-alpha/betaII, PDGFR-alpha, p-JNK, Ki-67, and bcl-2 antigens than their more mature-appearing chondrocytic counterparts in MC.
|
12817616 |
2003 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, we propose that CD99 is a potential action target of EPS11, inhibiting cancer cell proliferation, adhesion and migration.
|
30641946 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All together, our data provide evidence that the abrogation of CD99 in EWS tumor cells leads to produce and release EXOs capable to transfer their antineoplastic effects into the nearby tumor cells, suggesting a novel atypical role for these microvesicles in reversion of malignancy rather than in priming the soil for progression and metastatic seeding.
|
31209202 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD99, an over-expressed transmembrane protein in several malignancies, has been considered a potential target for immunotherapy.
|
30845661 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor showed strong expression of CD99, FLI1, and CD56 and was positive for the EWSR1-FLI1 fusion transcript.
|
31585812 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Morphological and immunohistochemical (SATB2, P-glycoprotein 1, CD99, caveolin 1) studies and gene expression profiling showed a remarkable similarity between patient's tumor and PDX, which was maintained over several passages in mice, whereas cell cultures displayed a lower correlation with human samples.
|
31434953 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, a morphological and immunohistochemical overlap existed between <i>BCOR</i>-rearrangement tumor and <i>BCOR</i>-ITD-positive tumor, including areas with hypercellularity alternating with hypocellularity, a mixture of round cells and focal spindle cells, pale nuclear chromatin, inconspicuous nucleoli and abundant myxoid matrix, diffuse strong cyclin D1 expression, relatively strong expression of CD99 but lower than that in Ewing sarcoma, and a low Ki-67 proliferation index of about 10%.
|
31632552 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pathologists should be aware that YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma is commonly positive with CD56 and CD99; as well as potentially assisting in diagnosis, positivity with these markers may also result in consideration of other neoplasms in the differential diagnosis.
|
30252726 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting of murine CD99 by a conjugate vaccine, which induced antibodies against CD99 in mice, resulted in inhibition of tumor growth in both a tumor model with high CD99 (Os-P0109 osteosarcoma) and low CD99 (CT26 colon carcinoma) expression.
|
31001265 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In light of the unusual findings in this case as well as the proximity of the EWSR1 locus and SMARCB1 locus on chromosome 22 and frequent CD99 staining in both tumors, we examined 16 ES cases and 17 ATRT, renal rhabdoid tumor (RRT), and extrarenal rhabdoid tumor (ERRT) cases for CD99 and INI1 staining and for EWSR1 rearrangement.
|
28382842 |
2019 |
|
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All together, our data provide evidence that the abrogation of CD99 in EWS tumor cells leads to produce and release EXOs capable to transfer their antineoplastic effects into the nearby tumor cells, suggesting a novel atypical role for these microvesicles in reversion of malignancy rather than in priming the soil for progression and metastatic seeding.
|
31209202 |
2019 |
|
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel therapeutic combination of anti-CD99 diabody C7 and irinotecan was tested against two EW PDX; both drugs inhibited PDX growth, the addition of anti-CD99 was beneficial when chemotherapy alone was less effective.
|
31434953 |
2019 |
|
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Staining with INI1 was negative in ATRT, RRT, and ERRT and positive in ES cases; CD99 was positive in ES cases and variable in ATRT cases.
|
28382842 |
2019 |
|
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD99 is a diagnostic marker for Ewing's Sarcoma (EWS), as it is highly expressed by these tumors.
|
31001265 |
2019 |
|
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positivity for CD99 and gata3 in the initial biopsy raised the differential diagnosis of Ewing sarcoma and poorly differentiated carcinoma.
|
31708666 |
2019 |
|
Ewings sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, a morphological and immunohistochemical overlap existed between <i>BCOR</i>-rearrangement tumor and <i>BCOR</i>-ITD-positive tumor, including areas with hypercellularity alternating with hypocellularity, a mixture of round cells and focal spindle cells, pale nuclear chromatin, inconspicuous nucleoli and abundant myxoid matrix, diffuse strong cyclin D1 expression, relatively strong expression of CD99 but lower than that in Ewing sarcoma, and a low Ki-67 proliferation index of about 10%.
|
31632552 |
2019 |
|
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the histopathological presence of Homer-Wright rosettes and immunohistochemical markers such as CD99, FLI-1 and CK are valuable factors for the diagnosis of ES, although cytogenetic analysis is considered the gold standard.
|
31788090 |
2019 |
|
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study performed NKX2.2, TLE1, and CD99 immunohistochemistry in a group of EWS and SSs confirmed by reverse transcription-polymerase chain reaction to evaluate the utility of these novel markers in this context.
|
28800015 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
All together, our data provide evidence that the abrogation of CD99 in EWS tumor cells leads to produce and release EXOs capable to transfer their antineoplastic effects into the nearby tumor cells, suggesting a novel atypical role for these microvesicles in reversion of malignancy rather than in priming the soil for progression and metastatic seeding.
|
31209202 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, we propose that CD99 is a potential action target of EPS11, inhibiting cancer cell proliferation, adhesion and migration.
|
30641946 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy.
|
29382926 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated TLE-1 and CD99 expression in various carcinomas and evaluated the expression of the SS18 (SYT) gene rearrangement (a characteristic biomarker for synovial sarcoma) in tumors with TLE-1 and/or CD99 expression.
|
27753659 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.
|
29534016 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we established that tumor suppressor CD99 is markedly downregulated in multiple myeloma.
|
29403080 |
2018 |